Abstract | IMPORTANCE: OBJECTIVE: DESIGN, SETTING, AND PARTICIPANTS: The DIABOLO study, a randomized, double-blind, multicenter trial, was conducted from October 2011 through July 2014 in 15 intensive care units (ICUs) in France. A total of 382 patients with COPD who were expected to receive mechanical ventilation for more 24 hours were randomized to the acetazolamide or placebo group and 380 were included in an intention-to treat analysis. INTERVENTIONS:
Acetazolamide (500-1000 mg, twice daily) vs placebo administered intravenously in cases of pure or mixed metabolic alkalosis, initiated within 48 hours of ICU admission and continued during the ICU stay for a maximum of 28 days. MAIN OUTCOMES AND MEASURES: The primary outcome was the duration of invasive mechanical ventilation via endotracheal intubation or tracheotomy. Secondary outcomes included changes in arterial blood gas and respiratory parameters, weaning duration, adverse events, use of noninvasive ventilation after extubation, successful weaning, the duration of ICU stay, and in-ICU mortality. RESULTS: Among 382 randomized patients, 380 (mean age, 69 years; 272 men [71.6%]; 379 [99.7%] with endotracheal intubation) completed the study. For the acetazolamide group (n = 187), compared with the placebo group (n = 193), no significant between-group differences were found for median duration of mechanical ventilation (-16.0 hours; 95% CI, -36.5 to 4.0 hours; P = .17), duration of weaning off mechanical ventilation (-0.9 hours; 95% CI, -4.3 to 1.3 hours; P = .36), daily changes of minute-ventilation (-0.0 L/min; 95% CI, -0.2 to 0.2 L/min; P = .72), or partial carbon-dioxide pressure in arterial blood (-0.3 mm Hg; 95% CI, -0.8 to 0.2 mm Hg; P = .25), although daily changes of serum bicarbonate (between-group difference, -0.8 mEq/L; 95% CI, -1.2 to -0.5 mEq/L; P < .001) and number of days with metabolic alkalosis (between-group difference, -1; 95% CI, -2 to -1 days; P < .001) decreased significantly more in the acetazolamide group. Other secondary outcomes also did not differ significantly between groups. CONCLUSIONS AND RELEVANCE: Among patients with COPD receiving invasive mechanical ventilation, the use of acetazolamide, compared with placebo, did not result in a statistically significant reduction in the duration of invasive mechanical ventilation. However, the magnitude of the difference was clinically important, and it is possible that the study was underpowered to establish statistical significance. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01627639.
|
Authors | Christophe Faisy, Ferhat Meziani, Benjamin Planquette, Marc Clavel, Arnaud Gacouin, Caroline Bornstain, Francis Schneider, Alexandre Duguet, Sébastien Gibot, Nicolas Lerolle, Jean-Damien Ricard, Olivier Sanchez, Michel Djibre, Jean-Louis Ricome, Antoine Rabbat, Nicholas Heming, Saïk Urien, Maxime Esvan, Sandrine Katsahian, DIABOLO Investigators |
Journal | JAMA
(JAMA)
Vol. 315
Issue 5
Pg. 480-8
(Feb 02 2016)
ISSN: 1538-3598 [Electronic] United States |
PMID | 26836730
(Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Bicarbonates
- Carbonic Anhydrase Inhibitors
- Carbon Dioxide
- Acetazolamide
|
Topics |
- Acetazolamide
(administration & dosage)
- Aged
- Alkalosis, Respiratory
(blood, therapy)
- Bicarbonates
(blood)
- Carbon Dioxide
(blood)
- Carbonic Anhydrase Inhibitors
(administration & dosage)
- Double-Blind Method
- Female
- Humans
- Intention to Treat Analysis
- Male
- Pulmonary Disease, Chronic Obstructive
(blood, therapy)
- Respiration, Artificial
(methods, statistics & numerical data)
- Time Factors
- Treatment Outcome
- Ventilator Weaning
(statistics & numerical data)
|
|
Join CureHunter, for free Research Interface BASIC access!
Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease.
Find out why thousands of doctors, pharma researchers and patient activists
around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!
|